Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abiraterone acetate - Johnson & Johnson

Drug Profile

Abiraterone acetate - Johnson & Johnson

Alternative Names: Abirateron-acetate-fine-particles; Aviraterone acetate; CB-7630; JNJ-212082; Zaitiga; Zaytiga; Zitiga; Zytiga

Latest Information Update: 08 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Institute of Cancer Research
  • Developer All Ireland Cooperative Oncology Research Group; Assistance Publique Hopitaux de Paris; Cancer Research UK; Cougar Biotechnology; Instituto do Cancer do Estado de Sao Paulo; Janssen Research & Development; Johnson & Johnson; UNICANCER
  • Class Androstenols; Antiandrogens; Antineoplastics; Small molecules
  • Mechanism of Action CYP17A1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Breast cancer; Ovarian cancer
  • No development reported Congenital adrenal hyperplasia

Most Recent Events

  • 24 Jan 2019 Phase-II clinical trials in Prostate cancer (Combination therapy) in Brazil (PO) (NCT02789878)
  • 26 Oct 2018 Janssen Research and Development completes a phase II trial for Prostate cancer (Combination therapy, Metastatic castration resistant disease, Second-line therapy or greater) in Brazil (PO) (NCT02217566)
  • 26 Oct 2018 Janssen Biotech has protection through regulatory excluvisity for abiraterone acetate in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top